ACADIA Pharmaceuticals (ACAD) opened 2026 with Q1 revenue of $268.1 million and basic EPS of $0.02, against a backdrop of trailing twelve month revenue of $1.1 billion, basic EPS of $2.22 and net income of $375.7 million. Over recent quarters, the company has seen revenue move from $244.3 million in Q1 2025 to $268.1 million in Q1 2026, while quarterly basic EPS has ranged from $0.11 to $1.62. These results come within a period of margin expansion and earnings growth that investors now need to judge for durability.

See our full analysis for ACADIA Pharmaceuticals.

From here, the key question is how these earnings and margin trends line up with the prevailing stories around ACAD, and where the hard numbers start to challenge those narratives.

Margins and profit growth stand out at 34.3%

• Over the last 12 months, ACADIA reported a net profit margin of 34.3% and earnings growth of 64.1%, with five year annual earnings growth averaging 69.4%. This is a strong combination of profitability and growth in the recent data.
• Bulls argue that this kind of profit profile can support long term earnings power, and the recent figures give them some backing, although with a few wrinkles:
  • The 64.1% one year earnings growth is slightly below the 69.4% five year average. The pace of profit expansion in the latest period is strong but not ahead of the longer trend.
  • Forecasts for 17.3% annual earnings growth still sit above the 10.1% revenue growth outlook. This fits the bullish view of profit growth outpacing sales even as margins are expected to ease.

Consistent profit expansion at this level is exactly what bullish investors point to when they say ACADIA could have more room to run if margins hold up over time, and they often use this backdrop as a springboard into a deeper bull vs bear debate about how long these trends can last. 🐂 ACADIA Pharmaceuticals Bull Case

P/E of 10.3x versus peers near 30x

• ACADIA trades on a trailing P/E of 10.3x compared with a peer average of 30.6x and a US biotechs industry average of 17.8x. The current share price of US$22.57 sits well below the DCF fair value of US$93.11 that is provided in the analysis.
• Bears highlight that even with this apparent discount, the future may be more constrained than the current multiples suggest, and the data gives them a few talking points:
  • Revenue growth is forecast at 10.1% a year compared with a 11.4% US market forecast. Top line growth in the outlook trails a simple market benchmark even though earnings forecasts are only modestly higher than the market at 17.3% versus 16.4%.
  • The model flags that one year earnings growth is below the five year average rate. Bears use this to argue that the most rapid phase of earnings expansion may already be in the rearview of the trailing data.

Skeptical investors sometimes see a low P/E and large gap to DCF fair value as a signal that the market is already baking in slower growth and margin pressure, and they lean on the more modest revenue outlook to support that cautious stance. 🐻 ACADIA Pharmaceuticals Bear Case

Quarterly EPS volatility versus steadier trailing year

• Quarterly basic EPS has swung from US$0.11 in Q1 2025 to US$1.62 in Q4 2025 and then US$0.02 in Q1 2026. Trailing twelve month basic EPS sits at US$2.22, which smooths out those short term jumps and dips.
• The consensus narrative that ACADIA has meaningful earnings power but faces real growth and concentration risks lines up with this mix of choppy quarters and solid trailing year:
  • On one hand, trailing twelve month revenue of about US$1.1b and net income of US$375.7 million support the idea of a business that is already scaled, not just a story tied to a single big quarter.
  • On the other hand, reliance on a narrow product set and forecasts that point to revenue growth of 10.1% a year, slightly behind the US market, give support to the view that future growth may not match the pace implied by the highest growth years in the recent past.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for ACADIA Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With all this in mind, sentiment around ACADIA is clearly mixed. It may make sense to move quickly and test the story against the data yourself. To see what investors are optimistic about, take a closer look at the 4 key rewards.

See What Else Is Out There

ACADIA’s softer revenue growth outlook versus the broader US market and reliance on a narrower product set leave you with meaningful concentration and growth risk.

If that mix feels uncomfortable, you could balance your portfolio by checking out the 72 resilient stocks with low risk scores to quickly spot companies where earnings profiles look more resilient and diversified.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.